Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families - PubMed (original) (raw)
. 2007 Mar 16;282(11):7825-32.
doi: 10.1074/jbc.M609168200. Epub 2007 Jan 22.
Affiliations
- PMID: 17244626
- DOI: 10.1074/jbc.M609168200
Free article
Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families
Minji Kim et al. J Biol Chem. 2007.
Free article
Abstract
Insulin-degrading enzyme (IDE) is a zinc metalloprotease that degrades the amyloid beta-peptide, the key component of Alzheimer disease (AD)-associated senile plaques. We have previously reported evidence for genetic linkage and association of AD on chromosome 10q23-24 in the region harboring the IDE gene. Here we have presented the first functional assessment of IDE in AD families showing the strongest evidence of the genetic linkage. We have examined the catalytic activity and expression of IDE in lymphoblast samples from 12 affected and unaffected members of three chromosome 10-linked AD pedigrees in the National Institute of Mental Health AD Genetics Initiative family sample. We have shown that the catalytic activity of cytosolic IDE to degrade insulin is reduced in affected versus unaffected subjects of these families. Further, we have shown the decrease in activity is not due to reduced IDE expression, suggesting the possible defects in IDE function in these AD families. In attempts to find potential mutations in the IDE gene in these families, we have found no coding region substitutions or alterations in splicing of the canonical exons and exon 15b of IDE. We have also found that total IDE mRNA levels are not significantly different in sporadic AD versus age-matched control brains. Collectively, our data suggest that the genetic linkage of AD in this set of chromosome 10-linked AD families may be the result of systemic defects in IDE activity in the absence of altered IDE expression, further supporting a role for IDE in AD pathogenesis.
Similar articles
- Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.
Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. Farris W, et al. Biochemistry. 2005 May 3;44(17):6513-25. doi: 10.1021/bi0476578. Biochemistry. 2005. PMID: 15850385 - Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain.
Blomqvist ME, Chalmers K, Andreasen N, Bogdanovic N, Wilcock GK, Cairns NJ, Feuk L, Brookes AJ, Love S, Blennow K, Kehoe PG, Prince JA. Blomqvist ME, et al. Neurobiol Aging. 2005 Jun;26(6):795-802. doi: 10.1016/j.neurobiolaging.2004.07.011. Neurobiol Aging. 2005. PMID: 15718037 Clinical Trial. - Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein.
Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ. Farris W, et al. Am J Pathol. 2004 Apr;164(4):1425-34. doi: 10.1016/s0002-9440(10)63229-4. Am J Pathol. 2004. PMID: 15039230 Free PMC article. - Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
Qiu WQ, Folstein MF. Qiu WQ, et al. Neurobiol Aging. 2006 Feb;27(2):190-8. doi: 10.1016/j.neurobiolaging.2005.01.004. Epub 2005 Feb 17. Neurobiol Aging. 2006. PMID: 16399206 Review. - [Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease].
Leal MC, Fernandez Gamba A, Morelli L, Castaño EM. Leal MC, et al. Medicina (B Aires). 2009;69(4):466-72. Medicina (B Aires). 2009. PMID: 19770104 Review. Spanish.
Cited by
- Characterization and modulation of human insulin degrading enzyme conformational dynamics to control enzyme activity.
Mancl JM, Liang WG, Bayhi NL, Wei H, Carragher B, Potter CS, Tang WJ. Mancl JM, et al. bioRxiv [Preprint]. 2025 Jan 4:2024.12.30.630732. doi: 10.1101/2024.12.30.630732. bioRxiv. 2025. PMID: 39803525 Free PMC article. Preprint. - Cell-permeable, small-molecule activators of the insulin-degrading enzyme.
Kukday SS, Manandhar SP, Ludley MC, Burriss ME, Alper BJ, Schmidt WK. Kukday SS, et al. J Biomol Screen. 2012 Dec;17(10):1348-61. doi: 10.1177/1087057112451921. Epub 2012 Jun 26. J Biomol Screen. 2012. PMID: 22740246 Free PMC article. - Involvement of insulin-degrading enzyme in the clearance of beta-amyloid at the blood-CSF barrier: Consequences of lead exposure.
Behl M, Zhang Y, Zheng W. Behl M, et al. Cerebrospinal Fluid Res. 2009 Sep 11;6:11. doi: 10.1186/1743-8454-6-11. Cerebrospinal Fluid Res. 2009. PMID: 19747378 Free PMC article. - Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cells.
Pivovarova O, Gögebakan O, Pfeiffer AF, Rudovich N. Pivovarova O, et al. Diabetologia. 2009 Aug;52(8):1656-64. doi: 10.1007/s00125-009-1350-7. Epub 2009 Apr 25. Diabetologia. 2009. PMID: 19396426 - Inositol phosphates and phosphoinositides activate insulin-degrading enzyme, while phosphoinositides also mediate binding to endosomes.
Song ES, Jang H, Guo HF, Juliano MA, Juliano L, Morris AJ, Galperin E, Rodgers DW, Hersh LB. Song ES, et al. Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2826-E2835. doi: 10.1073/pnas.1613447114. Epub 2017 Mar 21. Proc Natl Acad Sci U S A. 2017. PMID: 28325868 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous